These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 6658460)

  • 41. [Coagulation parameters in patients with hypertension].
    García E; Rodríguez M; Díez ML; Navarro A
    Rev Esp Fisiol; 1982; 38 Suppl():277-80. PubMed ID: 7146584
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Differences between functional and immunologic determinations of plasma antithrombin during the treatment of disseminated intravascular coagulation by infusion of antithrombin III concentrate.
    Jespersen J; Rasmussen NR; Sidelmann J
    Acta Chir Scand Suppl; 1982; 509():105-7. PubMed ID: 6962611
    [No Abstract]   [Full Text] [Related]  

  • 43. An antithrombin III assay based on factor Xa inhibition provides a more reliable test to identify congenital antithrombin III deficiency than an assay based on thrombin inhibition.
    Demers C; Henderson P; Blajchman MA; Wells MJ; Mitchell L; Johnston M; Ofosu FA; Fernandez-Rachubinski F; Andrew M; Hirsh J
    Thromb Haemost; 1993 Mar; 69(3):231-5. PubMed ID: 8470046
    [TBL] [Abstract][Full Text] [Related]  

  • 44. The effect of levenogesterol (Norplant) contraception on coagulation as measured by antithrombin-III levels.
    Pryor JA; Cooper KR; Bass JD; Hampton HL; Rock WA; Morrison JC
    J Miss State Med Assoc; 1996 Oct; 37(10):777-9. PubMed ID: 8908950
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Report of a novel kindred with antithrombin heparin-binding site variant (47 Arg to His): demand for an automated progressive antithrombin assay to detect molecular variants with low thrombotic risk.
    Rossi E; Chiusolo P; Za T; Marietti S; Ciminello A; Leone G; De Stefano V
    Thromb Haemost; 2007 Sep; 98(3):695-7. PubMed ID: 17849067
    [No Abstract]   [Full Text] [Related]  

  • 46. Detection of plasma endotoxin with a limulus amoebocyte lysate (LAL)-chromogenic substrate assay.
    Stemberger A; Strasser F; von Hundelshausen Bv; Tempel G; Blümel G
    Acta Chir Scand Suppl; 1982; 509():49-53. PubMed ID: 6962619
    [No Abstract]   [Full Text] [Related]  

  • 47. Inhibition of thrombin by antithrombin III and heparin cofactor II in vivo.
    Liu L; Dewar L; Song Y; Kulczycky M; Blajchman MA; Fenton JW; Andrew M; Delorme M; Ginsberg J; Preissner KT
    Thromb Haemost; 1995 Mar; 73(3):405-12. PubMed ID: 7545318
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [Standardization of coagulologic technique for antithrombin III estimation and its clinical application].
    Berkovskiĭ AL; Sergeeva EV; Kartoshkina AV; Suvorov AV
    Klin Lab Diagn; 2006 Aug; (8):29-30. PubMed ID: 17087244
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Disseminated intravascular coagulation: antithrombin, plasminogen, and coagulation abnormalities in 41 dogs.
    Feldman BF; Madewell BR; O'Neill S
    J Am Vet Med Assoc; 1981 Jul; 179(2):151-4. PubMed ID: 7263467
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Antithrombin III assay using thrombin in disseminated intravascular coagulation (DIC), other thromboembolic disorders and hepatic diseases.
    Saxena V; Mishra DK; Subramanya H; Satyanarayana S; Sharma A
    Indian J Pathol Microbiol; 2004 Apr; 47(2):210-2. PubMed ID: 16295470
    [TBL] [Abstract][Full Text] [Related]  

  • 51. [Antithrombin III: critical review of the methods used for its monitoring in thrombophilic states].
    Modiano A; Belisario A
    G Clin Med; 1981 Sep; 62(9):597-608. PubMed ID: 7033027
    [No Abstract]   [Full Text] [Related]  

  • 52. [Determination of the antithrombin III activity of the blood].
    Belitser VA; Musialkovskaia AA; Platonova TN; Ena IaM
    Lab Delo; 1987; (4):255-9. PubMed ID: 2439751
    [No Abstract]   [Full Text] [Related]  

  • 53. [Antithrombin III and its role in normal and pathological hemostasis].
    Bŭchvarova V; Doĭchinov A; Angelova N
    Vutr Boles; 1981; 20(6):34-8. PubMed ID: 7039127
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [Studies of antithrombin III assay using new chromogenic peptide substrates (author's transl)].
    Asai K; Takagi A; Inagaki Y; Setsuda Y
    Rinsho Byori; 1979 Dec; 27(12):1121-5. PubMed ID: 541858
    [No Abstract]   [Full Text] [Related]  

  • 55. Antithrombin III, protein S, and coagulation in the nephrotic syndrome.
    Schnaper HW
    Pediatr Nephrol; 2001 Jan; 16(1):98. PubMed ID: 11198616
    [No Abstract]   [Full Text] [Related]  

  • 56. [Activity of antithrombin III in the blood of patients with bladder cancer].
    Zietek Z; Iwan-Zietek I; Kotschy M; Wiśniewska E; Tyloch F
    Pol Merkur Lekarski; 1997 Apr; 2(10):268-9. PubMed ID: 9377663
    [TBL] [Abstract][Full Text] [Related]  

  • 57. On the mechanism of coagulation inhibition on surfaces with end point immobilized heparin.
    Elgue G; Blombäck M; Olsson P; Riesenfeld J
    Thromb Haemost; 1993 Aug; 70(2):289-93. PubMed ID: 8236137
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Monitoring complex formation in the blood-coagulation cascade using aptamer-coated SAW sensors.
    Gronewold TM; Glass S; Quandt E; Famulok M
    Biosens Bioelectron; 2005 Apr; 20(10):2044-52. PubMed ID: 15741074
    [TBL] [Abstract][Full Text] [Related]  

  • 59. [Antithrombin III determinations in internal medicine and surgery].
    Schmitz-Huebner U
    Med Lab (Stuttg); 1980 Sep; 33(9):232-5. PubMed ID: 7442606
    [No Abstract]   [Full Text] [Related]  

  • 60. Antithrombin deficiency in special clinical syndromes--Part II: panel discussion #2.
    Sacher R
    Semin Hematol; 1995 Oct; 32(4 Suppl 2):67-71. PubMed ID: 8821213
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.